PORTA, Camillo Guglielmo Giuseppe

PORTA, Camillo Guglielmo Giuseppe  

DIPARTIMENTO INTERDISCIPLINARE DI MEDICINA  

Mostra records
Risultati 1 - 20 di 230 (tempo di esecuzione: 0.037 secondi).
Titolo Data di pubblicazione Autore(i) File
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 1-gen-2021 Pezzicoli, Gaetano; Lovero, Domenica; Tucci, Marco; Porta, Camillo; Mannavola, Francesco
Abstract 2808: Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model 1-gen-2021 Mannavola, Francesco; Lovero, Domenica; Felici, Claudia; Stucci, Luigia Stefania; Porta, Camillo; Tucci, Marco
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 1-gen-2020 Cosmai, Laura; Porta, Camillo; Privitera, Carmelo; Gesualdo, Loreto; Procopio, Giuseppe; Gori, Stefania; Laghi, Andrea
Acute Kidney Injury in Cancer Patients 1-gen-2018 Gallieni, M.; Cosmai, L.; Porta, C.
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 1-gen-2016 Massari, F.; Modena, A.; Ciccarese, C.; Pilotto, S.; Maines, F.; Bracarda, S.; Sperduti, I.; Giannarelli, D.; Carlini, P.; Santini, D.; Tortora, G.; Porta, C.; Bria, E.
Adjuvant therapy in renal cell carcinoma 1-gen-2017 Massari, F.; Di Nunno, V.; Ciccarese, C.; Graham, J.; Porta, C.; Comito, F.; Cubelli, M.; Iacovelli, R.; Heng, D. Y. C.
The adjuvant treatment of kidney cancer: a multidisciplinary outlook 1-gen-2019 Porta, C.; Cosmai, L.; Leibovich, B. C.; Powles, T.; Gallieni, M.; Bex, A.
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 1-gen-2021 Mandriani, B.; Pelle', E.; Pezzicoli, G.; Strosberg, J.; Abate-Daga, D.; Guarini, A.; Cives, M.; Porta, C.
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 1-gen-2015 Rothermundt, C.; Bailey, A.; Cerbone, L.; Eisen, T.; Escudier, B.; Gillessen, S.; Grunwald, V.; Larkin, J.; Mcdermott, D.; Oldenburg, J.; Porta, C.; Rini, B.; Schmidinger, M.; Sternberg, C.; Putora, P. M.
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer 1-gen-2019 Del Re, M.; Crucitta, S.; Sbrana, A.; Rofi, E.; Paolieri, F.; Gianfilippo, G.; Galli, L.; Falcone, A.; Morganti, R.; Porta, C.; Efstathiou, E.; van Schaik, R.; Jenster, G.; Danesi, R.
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 1-gen-2022 Lauricella, Eleonora; Mandriani, Barbara; Cavallo, Federica; Pezzicoli, Gaetano; Chaoul, Nada; Porta, Camillo; Cives, Mauro
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review 1-gen-2019 Bracarda, S.; Porta, C.; Sabbatini, R.; Rivoltini, L.
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 1-gen-2020 Mantovani, S.; Varchetta, S.; Mele, D.; Donadon, M.; Torzilli, G.; Soldani, C.; Franceschini, B.; Porta, C.; Chiellino, S.; Pedrazzoli, P.; Santambrogio, R.; Barabino, M.; Cigala, C.; Piccolo, G.; Opocher, E.; Maestri, M.; Sangiovanni, A.; Bernuzzi, S.; Lhospice, F.; Kraiem, M.; Mondelli, M. U.; Oliviero, B.
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 1-gen-2022 Rebuzzi, S. E.; Cerbone, L.; Signori, A.; Santoni, M.; Murianni, V.; De Giorgi, U.; Procopio, G.; Porta, C.; Milella, M.; Basso, U.; Massari, F.; Maruzzo, M.; Iacovelli, R.; Battelli, N.; Carmisciano, L.; Banna, G. L.; Buti, S.; Fornarini, G.
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 1-gen-2020 Gentile, Marica; Centonza, Antonella; Lovero, Domenica; Palmirotta, Raffaele; Porta, Camillo; Silvestris, Franco; D'Oronzo, Stella
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 1-gen-2021 Santoni, M.; Piva, F.; Porta, C.; Bracarda, S.; Heng, D. Y.; Matrana, M. R.; Grande, E.; Mollica, V.; Aurilio, G.; Rizzo, M.; Giulietti, M.; Montironi, R.; Massari, F.
ASSURE vs. S-TRAC: Conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics 1-gen-2016 Porta, C.; Chiellino, S.
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 1-gen-2021 Rini, B. I.; Motzer, R. J.; Powles, T.; Mcdermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R.; Bracarda, S.; Bedke, J.; De Giorgi, U.; Porta, C.; Ravaud, A.; Parnis, F.; Grande, E.; Zhang, W.; Huseni, M.; Carroll, S.; Sufan, R.; Schiff, C.; Atkins, M. B.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial 1-gen-2019 Rini, B. I.; Powles, T.; Atkins, M. B.; Escudier, B.; Mcdermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; Hawkins, R.; Ravaud, A.; Alekseev, B.; Staehler, M.; Uemura, M.; De Giorgi, U.; Mellado, B.; Porta, C.; Melichar, B.; Gurney, H.; Bedke, J.; Choueiri, T. K.; Parnis, F.; Khaznadar, T.; Thobhani, A.; Li, S.; Piault-Louis, E.; Frantz, G.; Huseni, M.; Schiff, C.; Green, M. C.; Motzer, R. J.
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 1-gen-2021 Stucci, LUIGIA STEFANIA; Interno', Valeria; Tucci, MARCO GAETANO; Perrone, Martina; Mannavola, Francesco; Palmirotta, Raffaele; Porta, Camillo Guglielmo Giuseppe